Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kingswood drops after discounted take-private proposal from majority shareholder

(Sharecast News) - Shares in Kingswood Holdings tumbled on Wednesday after a heavily discounted takeover proposal from its majority shareholder, with the financial advice firm now out of options before it runs out of cash by the end of the month. HSQ Investments, which already owns 68.4% of Kingswood and has provided up to £80m in growth equity capital since its initial investment in 2019, has proposed buying the company at a price of just 7p per share.

That's down from Tuesday's closing price of 8.5p and well below the 12-13p level seen last summer, causing the stock to drop 12.9% to 7.4p in morning trade.

The share price has tanked over recent months as operations have been impacted by sector-wide headwinds, while Kingswood's acquisition strategy has resulted in a big ramp up of debt over the past two years.

The company, which had a net cash position of £39.7m two years ago, finished 2024 with £90.7m in gross debt and loans combined, including those provided by HSQ.

Now, imminent obligations well exceed the current cash balance available, meaning that - without further external financial support - Kingswood would not be able to meet its payments by the end of March.

"HSQ has confirmed that they continue to be supportive of the business but believe that this is most appropriate from a position as sole institutional shareholder alongside the company moving to an unlisted, private company setting and therefore they have stated that they would be willing to provide the required near-term funding only on this basis," Kingswood said in a statement.

"The Kingswood independent directors are strongly of the view that there is no other near term credible alternative to the company other than the continued financial support from HSQ."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.